SARS-CoV-2 Omicron infections pose long-COVID risks despite reduced severity NaturePortfolio lunduniversity SARSCoV2 COVID19 Coronavirus Omicron Severity
By Dr. Chinta SidharthanDec 2 2022Reviewed by Aimee Molineux In a recent study published in Nature Communications, researchers compared the post-coronavirus disease complaints and symptoms in individuals infected with the severe acute respiratory syndrome coronavirus 2 Omicron variant with those in individuals with Delta variant infections to understand whether the long-term complaints after Omicron infections are similar to those in infections with other SARS-CoV-2 variants.
About the study In the present study, the team conducted a prospective cohort analysis of Norwegian residents between the age of 18 and 70 years who had positive or negative SARS-CoV-2 polymerase chain reaction tests between December 8 and 31, 2021, when the Omicron and Delta variant circulations in Norway had a large overlap. Whole genome or Sanger sequencing data was used to identify the SARS-CoV-2 variant for all positive PCR tests.
A sensitivity analysis using a cohort of untested individuals was also performed to account for increased testing and primary healthcare visits by individuals who tested negative for SARS-CoV-2 but experienced persistent systems similar to those experienced by positive cases.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Frontiers | Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsAnti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of VHH1.1, a nanobody IgA fusion molecular as an inhalable, affordable and less invasive prophylactic and therapeutic treatment against SARS-CoV-2 Omicron variants. VHH-IgA 1.1 recognizes a conserved epitope of SARS-CoV-2 spike protein Receptor Binding Domain (RBD) and potently neutralizes major global SARS-CoV-2 variants of concern (VOC) including the Omicron variant and its sub lineages BA.1.1, BA.2 and BA.2.12.1. The IgA fusion of VHH1.1 is also much more potent against Omicron variants as compared to its IgG Fc fusion demonstrating the importance of IgA mediated mucosal protection for Omicron infection. Intranasal administration of VHH-IgA1.1 prior to or after challenge conferred significant protection from severe respiratory disease in K18-ACE2 transgenic mice infected with SARS-CoV-2 VOC. More importantly, for cost-effective production, VHH-IgA1.1 produced in Pichia pastoris had comparable potency as mammalian produced antibody. Our study demonstrates that intranasal administration of VHH-IgA fusion protein produced affordably provides effective mucosal immunity against infection of SARS-CoV-2 including the emerging variants.
Consulte Mais informação »
Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infectionPrior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection Coronavirus Disease COVID Omicron SARSCoV2 JIDJournal UNC ClevelandClinic
Consulte Mais informação »
FDA Pulls Covid Antibody Treatment Because It's Not Effective Against Dominant Omicron VariantsU.S. health officials have warned that people with weak immune systems face a heightened risk from COVID this winter, because omicron subvariants threaten to knock out antibody treatments.
Consulte Mais informação »
Risk factor assessment for the development of severe SARS-CoV-2 breakthrough infectionsresearchers evaluated the severity of breakthrough SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections and the risk factors associated with severity among individuals vaccinated for coronavirus disease 2019 (COVID-19) in Sousse, Tunisia.
Consulte Mais informação »
Researchers explore failed SARS-CoV-2 screening at hospital entrancesResearchers evaluated the failure rates of COVID-19 screening at hospital entrances for visitors, health professionals, and patients at the Yale New Haven Hospital in the US.
Consulte Mais informação »
The effect of ubiquitination on SARS-CoV-2 infection and patient prognosisA recent Clinical and Translational Medicine study utilized several published public datasets to evaluate the biological characteristics associated with the ubiquitination of patients infected with SARS-CoV-2.
Consulte Mais informação »